View clinical trials related to Gastro-Oesophageal Cancer.
Filter by:To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)